Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
Britain Courts Anthropic Amid US Defense Department Dispute 
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push 
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
Luxury Car Sales in the Middle East Take a Hit Amid Iran War 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom 
Apple Turns 50: From Garage Startup to AI Crossroads 
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026 
SAN FRANCISCO, Dec. 05, 2016 -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care solutions company focused on the advancement of cardiac care, today reported financial results for the three and nine months ended September 30, 2016.
Recent Highlights
- Achieved record revenue of $16.8 million in the third quarter of 2016, an increase of 80% over the same period of the prior year
- Completed initial public offering, receiving net proceeds of approximately $111 million
- Study results presented at the American Heart Association (AHA) Scientific Sessions suggest that extended continuous cardiac monitoring using its Zio® Service is more useful for arrhythmia detection than Holter monitoring in patients with adult congenital heart disease (ACHD).
"I am encouraged by the strong adoption we are experiencing for our Zio Service. To date, we have provided our service to more than 500,000 patients and received broad U.S. payor coverage estimated to be over 290 million patients,” said Kevin King, Chief Executive Officer. “I believe that our recent successful IPO will enable us to continue to expand our highly differentiated method of long term continuous cardiac monitoring, which improves arrhythmia detection and diagnosis by prescribing physicians and offers the potential to change clinical management of patients.”
Third Quarter Financial Results
Revenue for the three months ended September 30, 2016 increased 80% to $16.8 million, from $9.3 million during the same period of the prior year. The increase in revenue was due primarily to increased volume of the Zio Service.
Gross profit for the third quarter of 2016 was $11.5 million, or 69% gross margin, up from $5.6 million, or 60% gross margin, in the same period of the prior year.
Operating expenses for the third quarter of 2016 were $14.2 million, an increase of 28% compared to the same period of the prior year. The increase in operating expenses was driven primarily by selling, general and administrative expenses used to expand the company’s sales force and support the growth in operations.
Loss from operations for the third quarter of 2016 was $2.7 million, compared to $5.5 million for the same period of the prior year.
Cash, cash equivalents, and short-term investments were $5.8 million as of September 30, 2016. In October 2016, iRhythm completed an initial public offering, raising net proceeds of approximately $111 million, after deducting underwriting discounts and commissions and offering expenses.
Guidance for Full Year 2016
iRhythm projects revenue for full year 2016 to be in the range of $62.4 million to $62.9 million.
Webcast and Conference Call Information
iRhythm’s management team will host a conference call today beginning at 1:30 p.m. PT / 4:30 p.m. ET. Investors interested in listening to the conference call may do so by dialing (844) 348-0016 for domestic callers or (213) 358-0876 for international callers, and referencing Conference ID:12948667 or from the webcast on the “Investor Relations” section of the company’s website at: www.irhythmtech.com.
About iRhythm Technologies, Inc.
iRhythm is a commercial-stage digital health care company redefining the way cardiac arrhythmias are clinically diagnosed. The company combines wearable biosensor devices worn for up to 14 days and cloud-based data analytics with powerful proprietary algorithms that distill data from millions of heartbeats into clinically actionable information. The company believes improvements in arrhythmia detection and characterization have the potential to change clinical management of patients. The company’s platform, the Zio Service, has been provided to over 500,000 patients, accumulating more than 125 million hours of curated heartbeat data within iRhythm’s data repository.
Forward-Looking Statements
This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These statements include statements regarding financial guidance. Such statements are based on current assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties, many of which are beyond our control, include risks described in the section entitled “Risk Factors” and elsewhere in our third quarter Form 10-Q filing made with the Securities and Exchange Commission on December 5, 2016. These forward-looking statements speak only as of the date hereof and should not be unduly relied upon. iRhythm disclaims any obligation to update these forward-looking statements.
[Financial Tables to Follow]
| IRHYTHM TECHNOLOGIES, INC. | ||||||||
| Condensed Consolidated Balance Sheets | ||||||||
| (Unaudited) | ||||||||
| (In thousands, except share and per share data) | ||||||||
| September 30, 2016 | December 31, 2015 | |||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 5,761 | $ | 25,208 | ||||
| Accounts receivable, net | 9,308 | 5,577 | ||||||
| Inventory | 1,672 | 1,145 | ||||||
| Prepaid expenses and other current assets | 1,013 | 808 | ||||||
| Restricted cash | 91 | 91 | ||||||
| Total current assets | 17,845 | 32,829 | ||||||
| Property and equipment, net | 3,363 | 2,036 | ||||||
| Goodwill | 862 | 862 | ||||||
| Other assets | 5,310 | 2,145 | ||||||
| Total assets | $ | 27,380 | $ | 37,872 | ||||
| Liabilities, Convertible Preferred Stock and Stockholders’ Deficit | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 1,581 | $ | 1,459 | ||||
| Accrued liabilities | 6,894 | 6,699 | ||||||
| Deferred revenue | 850 | 506 | ||||||
| Accrued interest, current portion | - | 111 | ||||||
| Total current liabilities | 9,325 | 8,775 | ||||||
| Debt | 31,796 | 30,552 | ||||||
| Deferred rent, noncurrent portion | 27 | 28 | ||||||
| Accrued interest, net of current portion | 119 | 96 | ||||||
| Preferred stock warrant liabilities | 3,945 | 2,949 | ||||||
| Total liabilities | 45,212 | 42,400 | ||||||
| Commitments and contingencies | ||||||||
| Convertible preferred stock, $0.001 par value – 11,392,882 and 11,392,882 shares authorized at September 30, 2016 and December 31, 2015, respectively; 11,046,146 and 11,046,146 shares issued and outstanding at September 30, 2016 and December 31, 2015, respectively; aggregate liquidation preference of $117,495, and $117,495 at September 30, 2016 and December 31, 2015, respectively | 97,096 | 97,096 | ||||||
| Stockholders’ deficit: | ||||||||
| Common stock, $0.001 par value – 18,528,913 and 18,528,913 shares authorized at September 30, 2016 and December 31, 2015, respectively; 1,455,020 and 1,410,565 shares issued and outstanding at and September 30, 2016 December 31, 2015, respectively | 1 | 1 | ||||||
| Additional paid-in capital | 5,974 | 4,641 | ||||||
| Accumulated deficit | (120,903 | ) | (106,266 | ) | ||||
| Total stockholders’ deficit | (114,928 | ) | (101,624 | ) | ||||
| Total liabilities, convertible preferred stock and stockholders’ deficit | $ | 27,380 | $ | 37,872 | ||||
| IRHYTHM TECHNOLOGIES, INC. | ||||||||||||||||
| Condensed Consolidated Statements of Operations and Comprehensive Loss | ||||||||||||||||
| (Unaudited) | ||||||||||||||||
| (In thousands, except share and per share data) | ||||||||||||||||
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
| 2016 | 2015 | 2016 | 2015 | |||||||||||||
| Revenue | $ | 16,780 | $ | 9,344 | $ | 45,368 | $ | 25,286 | ||||||||
| Cost of revenue | 5,282 | 3,748 | 15,097 | 10,539 | ||||||||||||
| Gross profit | 11,498 | 5,596 | 30,271 | 14,747 | ||||||||||||
| Operating expenses: | ||||||||||||||||
| Research and development | 1,635 | 1,651 | 4,847 | 4,549 | ||||||||||||
| Selling, general and administrative | 12,529 | 9,445 | 36,658 | 24,935 | ||||||||||||
| Total operating expenses | 14,164 | 11,096 | 41,505 | 29,484 | ||||||||||||
| Loss from operations | (2,666 | ) | (5,500 | ) | (11,234 | ) | (14,737 | ) | ||||||||
| Interest expense | (807 | ) | (222 | ) | (2,388 | ) | (477 | ) | ||||||||
| Other expense, net | (602 | ) | (24 | ) | (1,015 | ) | 117 | |||||||||
| Net loss and comprehensive loss | $ | (4,075 | ) | $ | (5,746 | ) | $ | (14,637 | ) | $ | (15,097 | ) | ||||
| Net loss per common share, basic and diluted | $ | (2.80 | ) | $ | (4.07 | ) | $ | (10.20 | ) | $ | (11.07 | ) | ||||
| Weighted-average shares used to compute net loss per common share, basic and diluted | 1,454,307 | 1,409,758 | 1,434,583 | 1,364,366 | ||||||||||||
Investor Relations Contact: Lynn Pieper Lewis or Leigh Salvo (415) 937-5404 [email protected] Media Contact Aaron Murphy (415) 229-3331 [email protected]
